Efficacy and safety of tacrolimus therapy for lupus nephritis: A systematic review of clinical trials

Y. H. Lee, H. S. Lee, S. J. Choi, J. Dae Ji, G. G. Song

    Research output: Contribution to journalArticlepeer-review

    41 Citations (Scopus)

    Abstract

    The aim of this study was to assess the efficacy and safety of tacrolimus for the treatment of lupus nephritis (LN). A systematic review of clinical trials on tacrolimus in LN was conducted. Seven studies met the review inclusion criteria. Two studies were case-control studies, and five studies were open-label trials. One randomized controlled trial (RCT) found that tacrolimus significantly improved lupus nephritis disease activity index (LNDAI) as compared with a placebo, but no difference was observed between these two groups in terms of treatment-related adverse events. The other case-control study compared tacrolimus with standard protocols of oral cyclophosphamide or azathioprine for the treatment of membranous LN and found that efficacies were similar. All five open-label prospective studies concluded that tacrolimus is safe and effective as an induction and maintenance therapy for LN or for the treatment of LN with persistent proteinuria that failed to respond to prednisolone and immunosuppressants. In conclusion, this systematic review shows that tacrolimus may be effective as an induction and maintenance therapy for LN or as a treatment for LN with persistent proteinuria despite gold standard treatment. However, further RCTs are needed to compare tacrolimus with standard regimens for the treatment of LN.

    Original languageEnglish
    Pages (from-to)636-640
    Number of pages5
    JournalLupus
    Volume20
    Issue number6
    DOIs
    Publication statusPublished - 2011 May

    Keywords

    • lupus nephritis
    • systematic review
    • tacrolimus

    ASJC Scopus subject areas

    • Rheumatology

    Fingerprint

    Dive into the research topics of 'Efficacy and safety of tacrolimus therapy for lupus nephritis: A systematic review of clinical trials'. Together they form a unique fingerprint.

    Cite this